Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis

References

• DignassALindsayJOSturmASecond European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current managementJ Crohns Colitis2012610991103023040451
   PubMed Web of Science ®Google Scholar
• NunesTBarreiro-de AcostaMMarin-JimenezINosPSansMOral locally active steroids in inflammatory bowel diseaseJ Crohns Colitis20137318319122784947
   PubMed Web of Science ®Google Scholar
• O’DonnellSO’MorainCATherapeutic benefits of budesonide in gastroenterologyTher Adv Chronic Dis20101417718623251737
   PubMedGoogle Scholar
• GrossVOral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitisExpert Opin Pharmacother2008971257126518422482
   PubMed Web of Science ®Google Scholar
• DignassAVan AsscheGLindsayJOEuropean Crohn’s and Colitis Organisation (ECCO)The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current managementJ Crohns Colitis201041286221122489
   PubMed Web of Science ®Google Scholar
• HanauerSSandbornWJPerssonAPerssonTBudesonide as maintenance treatment in Crohn’s disease: a placebo-controlled trialAliment Pharmacol Ther200521436337115709986
   PubMed Web of Science ®Google Scholar
• SandbornWJLofbergRFeaganBGHanauerSBCampieriMGreenbergGRBudesonide for maintenance of remission in patients with Crohn’s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trialsAm J Gastroenterol200510081780178716086715
   PubMed Web of Science ®Google Scholar
• SherlockMESeowCHSteinhartAHGriffithsAMOral budesonide for induction of remission in ulcerative colitis [review]Cochrane Database Syst Rev201010CD00769820927762
   PubMed Web of Science ®Google Scholar
• SandbornWJTravisSMoroLOnce-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I studyGastroenterology2012143512181226. e1e222892337
   PubMed Web of Science ®Google Scholar
• MunchAAustDBohrJEuropean Microscopic Colitis Group (EMCG)Microscopic colitis: Current status, present and future challenges: statements of the European Microscopic Colitis GroupJ Crohns Colitis20126993294522704658
   PubMed Web of Science ®Google Scholar
• GentileNMAbdallaAAKhannaSOutcomes of patients with microscopic colitis treated with corticosteroids: a population-based studyAm J Gastroenterol2013108225625923295275
   PubMed Web of Science ®Google Scholar
• LofbergRDanielssonASaldeLOral budesonide in active Crohn’s diseaseAliment Pharmacol Ther1993766116168161666
   PubMed Web of Science ®Google Scholar
• Marin-JimenezIPenaASBudesonide for ulcerative colitisRev Esp Enferm Dig2006985362373 Spanish16944997
   PubMed Web of Science ®Google Scholar
• PatelNVPatelJKShahSHPatelJNCentral composite design for the formulation and optimization of a multi-unit potential colonic drug delivery system of budesonide for ulcerative colitisPharmazie201166212412921434575
   PubMed Web of Science ®Google Scholar
• BrunnerMZieglerSDi StefanoAFGastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulationBr J Clin Pharmacol2006611313816390349
   PubMed Web of Science ®Google Scholar
• FiorinoGFriesWDe La RueSAMalesciACRepiciADaneseSNew drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gutCurr Med Chem201017171851185720353384
   PubMed Web of Science ®Google Scholar
• De CassanCFiorinoGDaneseSSecond-generation corticosteroids for the treatment of Crohn’s disease and ulcerative colitis: more effective and less side effects?Dig Dis201230436837522796798
   PubMed Web of Science ®Google Scholar
• D’HaensGRKovacsAVergauwePClinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX(R) 9 mg extended-release tablets in patients with active left-sided ulcerative colitisJ Crohns Colitis20104215316021122499
   PubMed Web of Science ®Google Scholar
• BarnesPJMolecular mechanisms and cellular effects of glucocorticosteroidsImmunol Allergy Clin North Am200525345146816054537
   PubMed Web of Science ®Google Scholar
• SilvermanJOtleyABudesonide in the treatment of inflammatory bowel diseaseExpert Rev Clin Immunol20117441942821790284
   PubMed Web of Science ®Google Scholar
• ArdizzoneSBianchi PorroGComparative tolerability of therapies for ulcerative colitisDrug Saf200225856158212113642
   PubMed Web of Science ®Google Scholar
• LichtensteinGRBengtssonBHapten-WhiteLRutgeertsPOral budesonide for maintenance of remission of Crohn’s disease: a pooled safety analysisAliment Pharmacol Ther200929664365319035972
   PubMed Web of Science ®Google Scholar
• D’HaensGVerstraeteACheynsKAerdenIBouillonRRutgeertsPBone turnover during short-term therapy with methylprednisolone or budesonide in Crohn’s diseaseAliment Pharmacol Ther19981254194249663720
   PubMed Web of Science ®Google Scholar
• SchoonEJBollaniSMillsPRMatrix Study GroupBone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s diseaseClin Gastroenterol Hepatol20053211312115704045
   PubMed Web of Science ®Google Scholar
• BeaulieuDBAnanthakrishnanANIssaMBudesonide induction and maintenance therapy for Crohn’s disease during pregnancyInflamm Bowel Dis2009151252818680195
   PubMed Web of Science ®Google Scholar
• PietteVDauresJPDemolyPTreating allergic rhinitis in pregnancyCurr Allergy Asthma Rep20066323223816579874
   PubMed Web of Science ®Google Scholar
• NorjavaaraEde VerdierMGNormal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonideJ Allergy Clin Immunol2003111473674212704351
   PubMed Web of Science ®Google Scholar
• LundinPDEdsbackerSBergstrandMPharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn’s diseaseAliment Pharmacol Ther2003171859212492736
   PubMed Web of Science ®Google Scholar
• LevineAWeizmanZBroideEIsraeli Pediatric Gastroenterology Association Budesonide Study GroupA comparison of budesonide and prednisone for the treatment of active pediatric Crohn diseaseJ Pediatr Gastroenterol Nutr200336224825212548062
   PubMed Web of Science ®Google Scholar
• LevineAKoriMDinariGIsraeli Pediatric Budesonide Study GroupComparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn’s disease: a randomized placebo-controlled trialInflamm Bowel Dis20091571055106119229988
   PubMed Web of Science ®Google Scholar
• Escher JC; European Collaborative Research Group on Budesonide in PaediatricIBDBudesonide versus prednisolone for the treatment of active Crohn’s disease in children: a randomized, double-blind, controlled, multicentre trialEur J Gastroenterol Hepatol2004161475415095852
   PubMed Web of Science ®Google Scholar
• LofbergRDanielssonASuhrOOral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitisGastroenterology19961106171317188964395
   PubMed Web of Science ®Google Scholar
• GrossVBunganicIMikhailovaTLEfficacy and tolerability of a once daily treatment with budesonide capsules versus mesalamine granules for the treatment of active ulcerative colitis: a randomized, double-blind, double-dummy, multicenter studyGastroenterology20091365 Suppl 1A15
   Web of Science ®Google Scholar
• GrossVBunganicIBelousovaEAInternational BUC-57 Study Group3 g mesalazine granules are superior to 9 mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trialJ Crohns Colitis20115212913821453882
   PubMed Web of Science ®Google Scholar
• KellerRStollRFoersterECGutscheNDomschkeWOral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trialAliment Pharmacol Ther1997116104710529663828
   PubMed Web of Science ®Google Scholar
• KolkmanJJMollmannHWMollmannACEvaluation of oral budesonide in the treatment of active distal ulcerative colitisDrugs Today (Barc)200440758960115510233
   PubMed Web of Science ®Google Scholar
• ChopraAPardiDSLoftusEVJrBudesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practiceInflamm Bowel Dis2006121293216374255
   PubMed Web of Science ®Google Scholar
• SandbornWJDaneseSBallardEDEfficacy of budesonide MMx® 6 mg QD for the maintenance of remission in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use studyGastroenterology20121425 Suppl 1S564
   Web of Science ®Google Scholar
• GionchettiPRizzelloFPoggioliGOral budesonide in the treatment of chronic refractory pouchitisAliment Pharmacol Ther200725101231123617451569
   PubMed Web of Science ®Google Scholar
• Cabriada NunoJLHernandez MartinABernal MartinezAZabalza EstevezIOral budesonide in the treatment of chronic refractory pouchitisGastroenterol Hepatol2008318485489 Spanish18928746
   PubMedGoogle Scholar
• Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. The Danish Budesonide Study GroupScand J Gastroenterol19912612122512301763292
   PubMed Web of Science ®Google Scholar
• GomollonFHinojosaJNosPBudesonide and inflammatory bowel diseaseGastroenterol Hepatol19992210525532 Spanish10650668
   PubMedGoogle Scholar
• LemannMGalianARutgeertsPComparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitisAliment Pharmacol Ther1995955575628580278
   PubMed Web of Science ®Google Scholar
• HartmannFSteinJBudMesa-Study GroupClinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitisAliment Pharmacol Ther201032336837620491741
   PubMed Web of Science ®Google Scholar